1191044-58-2
基本信息
GSK-1059865 (GSK 1059865
Methanone, [(2S,5S)-2-[[(5-bromo-2-pyridinyl)amino]methyl]-5-methyl-1-piperidinyl](3-fluoro-2-methoxyphenyl)-
物理化学性质
| 沸点 | 575.8±50.0 °C(Predicted) |
| 密度 | 1.376±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO : ≥ 50 mg/mL (114.59 mM) |
| 酸度系数(pKa) | 4.89±0.10(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
1191044-58-2价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-101534 | 1191044-58-2 GSK1059865 | 1191044-58-2 | 5mg | 1950元 |
| 2024/04/30 | HY-101534 | 1191044-58-2 GSK1059865 | 1191044-58-2 | 10mM * 1mLin DMSO | 2150元 |
| 2024/04/30 | HY-101534 | 1191044-58-2 GSK1059865 | 1191044-58-2 | 25mg | 6200元 |
常见问题列表
Orexin 1 receptor
Treatment with GSK1059865 significantly decreases ethanol drinking in a dose-dependent manner in CIE-exposed mice. In contrast GSK1059865 decreases drinking in air-exposed mice only at the highest dose used. There is no effect of GSK1059865 on sucrose intake. GSK1059865 (0.3 nM-10 nM) produces non-surmountable antagonism with a dose-dependent rightward shift of the OXA EC 50 and a concomitant decrease of the agonist maximal response. The calculated pK B value is 8.77±0.12 for GSK1059865. GSK1059865 (0.1-3.3 μM) produces a classical surmountable profile with parallel rightward shift of the OXA EC 50 without depression of the agonist maximal response. Intraperitoneal administration of GSK1059865 produces a region-dependent inhibition of yohimbine-induced relative cerebral blood volume response. The administration of GSK1059865 per se produces a weak relative cerebral blood volume increase in several brain regions. GSK1059865-pretreated animals exhibit slightly higher baseline mean arterial blood pressure values than controls.